| Title |
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
|
|---|---|
| Published in |
Cochrane database of systematic reviews, July 2013
|
| DOI | 10.1002/14651858.cd006910.pub2 |
| Pubmed ID | |
| Authors |
Theresa A Lawrie, Andrew Bryant, Alison Cameron, Emma Gray, Jo Morrison |
| Abstract |
Ovarian cancer is the eighth most common cancer in women and it is usually diagnosed at an advanced stage. The majority of ovarian tumours are epithelial in origin. Women with relapsed epithelial ovarian cancer (EOC) often have a reduced performance status with a limited life expectancy, therefore maintaining quality of life with effective symptom control is the main purpose of treatment. Drug treatment of relapsed disease is directed by the platinum-free interval: relapsed platinum-sensitive disease is usually re-treated with platinum-based therapy and platinum-resistant disease challenged with non-platinum drugs. However, the side-effects of chemotherapy agents may be severe and optimal treatment regimens are unclear. Pegylated liposomal doxorubicin (PLD), which contains a cytotoxic drug called doxorubicin hydrochloride is one of several treatment modalities that may be considered for single-agent treatment of relapsed EOC, or used in combination with other drugs. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 25% |
| India | 1 | 13% |
| Unknown | 5 | 63% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 75% |
| Science communicators (journalists, bloggers, editors) | 1 | 13% |
| Practitioners (doctors, other healthcare professionals) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 197 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 1% |
| Spain | 1 | <1% |
| Ecuador | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 192 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 29 | 15% |
| Student > Bachelor | 22 | 11% |
| Researcher | 21 | 11% |
| Other | 19 | 10% |
| Student > Ph. D. Student | 18 | 9% |
| Other | 28 | 14% |
| Unknown | 60 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 81 | 41% |
| Nursing and Health Professions | 13 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 4% |
| Agricultural and Biological Sciences | 6 | 3% |
| Biochemistry, Genetics and Molecular Biology | 5 | 3% |
| Other | 22 | 11% |
| Unknown | 63 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2023.
All research outputs
#3,249,652
of 25,658,541 outputs
Outputs from Cochrane database of systematic reviews
#5,980
of 13,150 outputs
Outputs of similar age
#26,475
of 207,066 outputs
Outputs of similar age from Cochrane database of systematic reviews
#156
of 333 outputs
Altmetric has tracked 25,658,541 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,150 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.7. This one has gotten more attention than average, scoring higher than 54% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,066 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 333 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.